Dr Reddy's Laboratories Ltd (STU:RDDA)
€ 13.3 -0.2 (-1.48%) Market Cap: 11.08 Bil Enterprise Value: 10.96 Bil PE Ratio: 23.15 PB Ratio: 3.28 GF Score: 90/100

Dr.Reddy's Laboratories Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 04:00PM GMT
Release Date Price: €11.7 (-0.85%)
Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst

Hello, and welcome to the JPMorgan Healthcare Conference. I am Neha Manpuria, the India Health Care Analyst at JPMorgan. It's my pleasure to introduce Mr. Erez Israeli, the CEO of Dr. Reddy's. We will be having a fireside chat in this session and try to address questions on growth strategies of Reddy's. Thank you so much for joining us for this session, sir. It is a pleasure to host you. If you don't mind me directly moving into Q&A, I can start.

Questions & Answers

Erez Israeli;s Laboratories Limited;CEO;Member of the Management Council
Dr. Reddy

'-&

Sure. Thank you for having me.

Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst

So the first question that I have is Dr. Reddy's today probably has a very well-balanced business with a growing emerging market presence, improving position in India post the Wockhardt acquisition and a strong U.S. pipeline. From here on,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot